Archive
551 articles, sorted by publication time.
Chai-2 pushes the most expensive and time-consuming early search in antibody discovery toward a stage where models can directly propose candidate molecules; a Nature paper and subsequent company materials show it has achieved wet-lab hit rates, but affinity, manufacturability, safety, and clinical validation still stand between it and a drug.
A Nature Medicine study turns routine chest CT into a tool for assessing heart disease and stroke risk, suggesting that the value of medical imaging lies not only in immediate diagnosis but may also be hidden in prognostic information that clinical workflows have not yet fully used.
UCI Health has launched the first human trial of a neural stem cell therapy, moving Huntington’s disease treatment from symptom control toward the possibility of cell replacement; but the first question this step must answer is whether implantation and long-term follow-up can be done safely.
A 23-year-old patient completed a Casgevy gene-editing treatment course in New Orleans, becoming the first publicly announced functional cure case in Louisiana and the southern U.S. Gulf region; this is not only a turning point in one individual’s disease course, but also shows that expensive, complex cell therapies are beginning to face real-world testing.
As new drugs, manufacturing, and biosecurity are all folded into national competition, the biotech industry’s anxiety is no longer just about a funding winter, but whether institutions can keep pace with the speed of science.
The same antibody drug, shifted from intravenous infusion to subcutaneous injection, changes not only administration time but may also reshape the treatment rhythm among patients, healthcare professionals, and medical institutions.
In the stage of multiple sclerosis when relapses are no longer obvious but disability continues to advance, treatment options have long been limited. Cenrifki’s EU approval shifts the focus from controlling attacks to slowing functional loss, but beyond efficacy, the risk of liver injury will also be a necessary premise for clinical use.
Beyond vaccines, capital is looking for another line of defense against influenza. RQ Bio’s new funding shows that the idea of preventive drugs still has a market, but the real answer must come from clinical evidence.
Cash flow from weight-loss drugs is being invested by Lilly into an R&D platform resembling an “app store”; the real test is not the buzz around computing power, but whether data from small biotech companies can be securely pooled and converted into verifiable drug hypotheses.
The new collaboration between Insilico Medicine and SK Biopharmaceuticals brings AI drug design into the difficult terrain where neurology and immunology intersect; but beyond the thin public details, the more critical question is whether candidate drugs can move out of models and into verifiable human evidence.
The focus of this release is not just another large model, but the linking of protein language models, structure prediction, and a billion-scale structural atlas into a toolchain that researchers can test. It makes the promise of AI-designed proteins more concrete, while also clarifying the distance between experimental validation and clinical translation.
The decision shifts the timing of type 1 diabetes care earlier: no longer only adding insulin after symptoms appear, but giving high-risk people a longer symptom-free period while the immune attack can still be delayed.